Celcuity Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024, reporting increased operating expenses and net losses as it continued to advance its clinical pipeline. Total operating expenses for Q4 2024 were $36.4 million, up from $19.7 million in Q4 2023.
For the full year 2024, total operating expenses reached $113.3 million, compared to $66.2 million in 2023. Research and development (R&D) expenses for the full year increased by $43.6 million to $104.2 million, primarily due to costs associated with the VIKTORIA-1, CELC-G-201, and VIKTORIA-2 Phase 3 trials.
The net loss for Q4 2024 was $36.7 million, or $0.85 loss per share, while the full year 2024 net loss was $111.8 million, or $2.83 loss per share. Net cash used in operating activities for the full year 2024 was $83.5 million.
As of December 31, 2024, Celcuity reported cash, cash equivalents, and short-term investments of approximately $235.1 million, which is expected to fund clinical development activities through 2026. The company anticipates a transformational 2025 with topline data for the VIKTORIA-1 PIK3CA wild-type cohort expected in Q2 2025, and data for the CELC-G-201 trial in mCRPC also in late Q2 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.